Patents by Inventor Christopher Kent ARNATT

Christopher Kent ARNATT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dibenzothiophene derivatives and methods of treating cancer therewith
    Patent number: 11890268
    Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: February 6, 2024
    Assignee: Saint Louis University
    Inventors: Ryan D. McCulla, Ankita Isor, Christopher Kent Arnatt
  • Compounds and methods targeting GPER in calcium disorders
    Patent number: 11634378
    Abstract: The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 25, 2023
    Assignee: SAINT LOUIS UNIVERSITY
    Inventors: Christopher Kent Arnatt, Chelsea DeLeon
  • COMPOUNDS AND METHODS TARGETING GPER FOR TREATMENT OF DISEASES ASSOCIATED WITH CALCIUM
    Publication number: 20210246127
    Abstract: In one aspect, the present disclosure provides compounds of the formula (I): In other aspects, the present disclosure provides compositions and methods of targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, cardiovascular disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 12, 2021
    Applicant: St. Louis University
    Inventors: Christopher Kent ARNATT, Chelsea SONDERGARD
  • PHOTOSWITCHABLE DIBENZOTHIENYLMETHYL TRIPHENYLPHOSPHONIUM DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH
    Publication number: 20210147378
    Abstract: In one aspect, the present disclosure provides a compound of the formula: In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 20, 2021
    Applicant: Saint Louis University
    Inventors: Ryan D. MCCULLA, Ankita ISOR, Christopher Kent ARNATT
  • COMPOUNDS AND METHODS TARGETING GPER IN CALCIUM DISORDERS
    Publication number: 20210087134
    Abstract: The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.
    Type: Application
    Filed: March 29, 2018
    Publication date: March 25, 2021
    Applicant: Saint Louis University
    Inventors: Christopher Kent ARNATT, Chelsea Sondergard
  • DIBENZOTHIOPHENE DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH
    Publication number: 20210077458
    Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 18, 2021
    Applicant: Saint Louis University
    Inventors: Ryan D. MCCULLA, Ankita ISOR, Christopher Kent ARNATT
  • COMPOUNDS AND METHODS TARGETING GPER IN CANCER
    Publication number: 20180289676
    Abstract: The present disclosure provides compounds, compositions and method targeting GPER for the treatment of disorders and disease such as cancers, gallstone disease and for neuroprotection. In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein for the treatment of disease including cancers, hormonal cancers, breast cancers including triple negative breast cancer, and leukemias.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 11, 2018
    Inventors: Christopher Kent ARNATT, Austin O'DEA